Literature DB >> 15097958

Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis.

Alexander Kreuter1, Frank Breuckmann, Andrea Uhle, Norbert Brockmeyer, Gregor Von Kobyletzki, Marcus Freitag, Markus Stuecker, Klaus Hoffmann, Thilo Gambichler, Peter Altmeyer.   

Abstract

BACKGROUND: Increased collagen synthesis, vascular damage, and T-lymphocytic infiltration contribute to the development of systemic sclerosis. Preliminary studies revealed the effectiveness of low-dose UVA1 phototherapy in acrosclerosis.
OBJECTIVE: We sought to confirm data of a pilot study revealing the efficacy of low-dose UVA1 irradiation in acrosclerosis in a larger number of patients.
METHODS: Symptoms of 18 patients receiving low-dose UVA1 phototherapy were evaluated clinically and biometrically in an open, nonrandomized study. A number of pretherapeutic and posttherapeutic biopsy specimens were tested immunohistochemically for matrix-metalloproteinase-1.
RESULTS: UVA1 irradiation led to softening of former stiffness reflected by a significant decrease of the hand score, increase of total skin distension, and reduction of skin thickness. Posttherapeutically, matrix-metalloproteinase-1 immunolabeling revealed a significant dermal elevation of collagenase.
CONCLUSION: Low-dose UVA1 phototherapy is a capable treatment option for acrosclerosis. Its beneficial effect may be mediated by the induction of collagenases and a reduction of collagen deposition and cellular infiltration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15097958     DOI: 10.1016/j.jaad.2003.08.026

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

Review 1.  [Scleredema adultorum : Clinical presentation, diagnostic workup, differential diagnosis, treatment option].

Authors:  A Kreuter
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

2.  Low-dose Ultraviolet A1 Phototherapy for Treating Pityriasis Rosea.

Authors:  Sang Hee Lim; Sang Min Kim; Byung Ho Oh; Jong Hyun Ko; Yang Won Lee; Yong Beom Choe; Kyu Joong Ahn
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

Review 3.  Scleroderma therapy: clinical overview of current trends and future perspective.

Authors:  Afsha A Topal; Rachita S Dhurat
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

Review 4.  [Current treatment of systemic scleroderma].

Authors:  Nicolas Hunzelmann
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

5.  UVA1 a promising approach for scleroderma.

Authors:  Uma Keyal; Anil Kumar Bhatta; Xiu Li Wang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

6.  Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy.

Authors:  Frank Wang; Luis A Garza; Soyun Cho; Reza Kafi; Craig Hammerberg; Taihao Quan; Ted Hamilton; Maureen Mayes; Voravit Ratanatharathorn; John J Voorhees; Gary J Fisher; Sewon Kang
Journal:  Arch Dermatol       Date:  2008-07

Review 7.  UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review.

Authors:  Frank Breuckmann; Thilo Gambichler; Peter Altmeyer; Alexander Kreuter
Journal:  BMC Dermatol       Date:  2004-09-20

Review 8.  Updates on morphea: role of vascular injury and advances in treatment.

Authors:  Julio C Sartori-Valinotti; Megha M Tollefson; Ann M Reed
Journal:  Autoimmune Dis       Date:  2013-11-12

Review 9.  Emerging treatments for scleroderma/systemic sclerosis.

Authors:  Jane L Zhu; Samantha M Black; Henry W Chen; Heidi T Jacobe
Journal:  Fac Rev       Date:  2021-05-05

Review 10.  Phototherapy in Scleroderma.

Authors:  John Hassani; Steven R Feldman
Journal:  Dermatol Ther (Heidelb)       Date:  2016-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.